Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ERNA
ERNA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ERNA News
Ernexa Therapeutics Hosts Investor Webcast
Feb 20 2026
Newsfilter
ZIM Integrated Shipping Shares Surge 38.1% in Pre-Market Trading
Feb 17 2026
Benzinga
U.S. Stocks Rise, AutoNation Shares Surge
Feb 06 2026
Benzinga
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 600 Points
Feb 06 2026
Benzinga
Ernexa Therapeutics Prices Public Offering at $0.50 per Share
Feb 06 2026
Newsfilter
Ernexa Therapeutics Advances Cell Therapy for Cancer Treatment
Feb 03 2026
Newsfilter
Penguin Solutions Reports Q1 Earnings of $0.49, Shares Up 5.3%
Jan 07 2026
Benzinga
Ernexa Therapeutics Targets 2026 for First-in-Human Ovarian Cancer Trial
Jan 06 2026
Globenewswire
Ernexa Therapeutics to Showcase at Oxford Global's Cell 2025 Event
Nov 11 2025
Newsfilter
Ernexa Therapeutics Highlights Collaboration with Cellipont Bioservices to Progress Towards First-in-Human Trials on Virtual Investor "What This Means" Platform
Nov 06 2025
Newsfilter
Three Penny Stocks to Keep an Eye on as of October 30, 2025
Oct 30 2025
TipRanks
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
Oct 29 2025
PRnewswire
Ernexa Therapeutics to Showcase New Findings in Oral Presentation at AACR Special Conference on Cancer Research
Sep 17 2025
Newsfilter
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Jun 25 2025
Newsfilter
Insider Purchase: 10% owner at $ERNA Buys 21,241,163 Shares
Jun 12 2025
NASDAQ.COM
Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance
Jun 10 2025
NASDAQ.COM
Show More News
